Obesity and Prostate Cancer - Microenvironmental Roles of Adipose Tissue
Overview
Affiliations
Obesity is known to have important roles in driving prostate cancer aggressiveness and increased mortality. Multiple mechanisms have been postulated for these clinical observations, including effects of diet and lifestyle, systemic changes in energy balance and hormonal regulation and activation of signalling by growth factors and cytokines and other components of the immune system. Over the past decade, research on obesity has shifted towards investigating the role of peri-prostatic white adipose tissue as an important source of locally produced factors that stimulate prostate cancer progression. Cells that comprise white adipose tissue, the adipocytes and their progenitor adipose stromal cells (ASCs), which proliferate to accommodate white adipose tissue expansion in obesity, have been identified as important drivers of obesity-associated cancer progression. Accumulating evidence suggests that adipocytes are a source of lipids that are used by adjacent prostate cancer cells. However, results of preclinical studies indicate that ASCs promote tumour growth by remodelling extracellular matrix and supporting neovascularization, contributing to the recruitment of immunosuppressive cells, and inducing epithelial-mesenchymal transition through paracrine signalling. Because epithelial-mesenchymal transition is associated with cancer chemotherapy resistance and metastasis, ASCs are considered to be potential targets of therapies that could be developed to suppress cancer aggressiveness in patients with obesity.
Demarchis L, Chiloiro S, Giampietro A, De Marinis L, Bianchi A, Fleseriu M Rev Endocr Metab Disord. 2025; .
PMID: 40088375 DOI: 10.1007/s11154-025-09957-6.
Li X, Yang F, Wang M, Huang X, Zeng X, Zhou L Front Pharmacol. 2025; 16:1478331.
PMID: 40078274 PMC: 11897510. DOI: 10.3389/fphar.2025.1478331.
Editorial: Obesity and cancer: the possible molecular links.
Basu B, Chakroborty D, Sarkar C Front Cell Dev Biol. 2025; 13:1542429.
PMID: 40008101 PMC: 11850323. DOI: 10.3389/fcell.2025.1542429.
Improving drug repositioning with negative data labeling using large language models.
Picard M, Leclercq M, Bodein A, Scott-Boyer M, Perin O, Droit A J Cheminform. 2025; 17(1):16.
PMID: 39905466 PMC: 11796214. DOI: 10.1186/s13321-025-00962-0.
Trecarten S, Liss M, Hamilton-Reeves J, DiGiovanni J Front Immunol. 2025; 15():1448116.
PMID: 39840030 PMC: 11747771. DOI: 10.3389/fimmu.2024.1448116.